Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Analyst Ratings
Strong Buy
19 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ALNY Stock 12 Month Forecast
Average Price Target
$317.29
▲(22.32% Upside)
| Highest Price Target$390.00 | Average Price Target$317.29 | Lowest Price Target$206.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Chardan Capital
Reiterated
05/02/25
Piper Sandler
Reiterated
05/02/25
William Blair
Reiterated
05/01/25
Canaccord Genuity
Reiterated
05/01/25
Bank of America Securities
Reiterated
05/01/25
Morgan Stanley
$268→$287
Hold
10.64%
Upside
Reiterated
05/01/25
Alnylam Pharma: Hold Rating Amid Steady Growth and Market Uncertainties
Needham
$320
Buy
23.37%
Upside
Reiterated
05/01/25
Alnylam Pharma's Growth Potential: Buy Rating Backed by Strong Sales and Future Projections
BMO Capital
$300
Buy
15.66%
Upside
Reiterated
04/30/25
Alnylam Pharma: Strong Buy Rating Driven by Robust RNAi Portfolio and Market Expansion
RBC Capital
$330
Buy
27.22%
Upside
Reiterated
04/29/25
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Alnylam Pharma (ALNY)
Cantor Fitzgerald
$250
Hold
-3.62%
Downside
Initiated
04/28/25
Cantor Fitzgerald starts Alnylam Pharmaceuticals (ALNY) at NeutralCantor Fitzgerald analyst Steven Seedhouse initiates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Neutral rating and a price target of $250.00.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Chardan Capital
Reiterated
05/02/25
Piper Sandler
Reiterated
05/02/25
William Blair
Reiterated
05/01/25
Canaccord Genuity
Reiterated
05/01/25
Bank of America Securities
Reiterated
05/01/25
Morgan Stanley
$268→$287
Hold
10.64%
Upside
Reiterated
05/01/25
Alnylam Pharma: Hold Rating Amid Steady Growth and Market Uncertainties
Needham
$320
Buy
23.37%
Upside
Reiterated
05/01/25
Alnylam Pharma's Growth Potential: Buy Rating Backed by Strong Sales and Future Projections
BMO Capital
$300
Buy
15.66%
Upside
Reiterated
04/30/25
Alnylam Pharma: Strong Buy Rating Driven by Robust RNAi Portfolio and Market Expansion
RBC Capital
$330
Buy
27.22%
Upside
Reiterated
04/29/25
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Alnylam Pharma (ALNY)
Cantor Fitzgerald
$250
Hold
-3.62%
Downside
Initiated
04/28/25
Cantor Fitzgerald starts Alnylam Pharmaceuticals (ALNY) at NeutralCantor Fitzgerald analyst Steven Seedhouse initiates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Neutral rating and a price target of $250.00.
Best Analysts Covering Alnylam Pharma
Which Analyst Should I Follow If I Want to Buy ALNY and Sell After:
1 Month
xxx
Success Rate
14/25 ratings generated profit
Average Return
+0.23%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.00% of your transactions generating a profit, with an average return of +0.23% per trade.
3 Months
xxx
Success Rate
22/39 ratings generated profit
Average Return
+3.50%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.41% of your transactions generating a profit, with an average return of +3.50% per trade.
1 Year
Success Rate
20/30 ratings generated profit
Average Return
+25.23%
reiterated a buy rating 4 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +25.23% per trade.
2 Years
xxx
Success Rate
32/39 ratings generated profit
Average Return
+36.23%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 82.05% of your transactions generating a profit, with an average return of +36.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ALNY Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
5
6
8
9
5
Buy
22
28
48
48
42
Hold
8
6
10
14
11
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
40
66
71
58
Each month's total comprises the sum of three months' worth of ratings.
ALNY Financial Forecast
ALNY Stock Forecast FAQ
What is ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 317.29.
What is ALNY’s upside potential, based on the analysts’ average price target?
Alnylam Pharmaceuticals has 22.32% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALNY a Buy, Sell or Hold?
Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.
What is Alnylam Pharmaceuticals’s price target?
The average price target for Alnylam Pharmaceuticals is 317.29. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $390.00 ,the lowest forecast is $206.00. The average price target represents 22.32% Increase from the current price of $259.39.
The highest analyst price target is $390.00 ,the lowest forecast is $206.00. The average price target represents 22.32% Increase from the current price of $259.39.
What do analysts say about Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.
How can I buy shares of ALNY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.